IP Library Granted Patent US 11,491,118
Granted Patent B2
US 11,491,118 · App. 17/394,710 · Granted Nov 8, 2022

Composition comprising cannabinoids for relief of pain

Inventors: Mark Andrew Hetherington (Toronto, CA); Chris Schnarr (Toronto, CA)
Assignee: TWEED INC.
A61K31/05A61K9/0014A61K31/165A61K31/192A61K31/196A61K31/606A61K36/28A61K36/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,491,118
App. No.
17/394,710
Granted
Nov 8, 2022
Kind
B2
Abstract

The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

Claims (32)

1. A composition for topical application comprising:

at least one purified cannabinoid;

at least one anti-inflammatory agent in an amount ranging from between about 5 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; and

at least one botanical extract, wherein the botanical extract is arnica;

wherein the composition is an ointment, a gel, a cream, an oil, a wax, a paste, or a fluid.

2. The composition of claim 1 , wherein the at least one purified cannabinoid is cannabidiol (CBD), tetrahydrocannabinol (THC), cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), cannabichromene acid (CBCA), tetrahydrocannabinolic acid (THCA) or cannabidiolic A (CBDA).

3. The composition of claim 1 , wherein the at least one purified cannabinoid is cannabidiol (CBD).

4. The composition of claim 1 , further comprising a terpene or terpenoid.

5. The composition of claim 4 , wherein the terpene or terpenoid is menthol, camphor, or a combination thereof.

6. The composition of claim 5 , wherein the terpene is an isolate, an extract or a distillate.

7. The composition of claim 1 , further comprising a flavonoid.

8. The composition of claim 7 , wherein the flavonoid is an isolate, an extract or a distillate.

9. The composition of claim 1 , wherein the at least one purified cannabinoid is present in an amount ranging from between about 0.5 wt % and about 10 wt % of the total weight of the composition.

10. The composition of claim 1 , wherein the at least one purified cannabinoid is present in an amount ranging from between about 2 wt % and about 8 wt % of the total weight of the composition.

11. The composition of claim 1 , wherein the at least one purified cannabinoid is present in an amount ranging from between about 2 wt % and about 6 wt % of the total weight of the composition.

12. The composition of claim 1 , wherein the at least one anti-inflammatory agent is present in an amount ranging from between about 5 wt % and about 25 wt % of the total weight of the composition.

13. The composition of claim 1 , wherein the at least one anti-inflammatory agent is present in an amount ranging from between about 5 wt % and about 10 wt % of the total weight of the composition.

14. The composition of claim 1 , wherein the at least one botanical extract is present in an amount ranging from between about 0.5 wt % and about 90 wt % of the total weight of the composition.

15. The composition of claim 1 , wherein the at least one botanical extract is present in an amount ranging from between about 1 wt % and about 25 wt % of the total weight of the composition.

16. The composition of claim 1 , wherein the at least one botanical extract is present in an amount ranging from between about 0.5 wt % and about 10 wt % of the total weight of the composition.

17. A composition for topical application comprising:

at least one purified cannabinoid in an amount of between about 0.5 wt % and about 10 wt % of the total weight of the composition;

at least one anti-inflammatory agent in an amount of between about 5 wt % and about 10 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; and

at least one botanical extract in an amount of between about 1 wt % and about 25 wt % of the total weight of the composition, wherein the botanical extract is arnica,

wherein the composition is an ointment, a gel, a cream, an oil, a wax, a paste, or a fluid.

18. A composition for topical application comprising:

at least one purified cannabinoid;

at least one anti-inflammatory agent in an amount of between about 5 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate;

at least one botanical extract in an amount of between about 0.5 wt % and about 90 wt % of the total weight of the composition, wherein the botanical extract is arnica; and

a terpene or terpenoid, wherein the terpene or terpenoid is menthol, camphor, or a combination thereof,

wherein the composition is an ointment, a gel, a cream, an oil, a wax, a paste, or a fluid.

19. A method for relieving pain in a subject, the method comprising administering to the subject the composition as defined in claim 1 .

Assignments (5)
SECURITY INTEREST Recorded Jan 20, 2026
From: CANOPY GROWTH CORPORATION; TWEED INC.
To: JGB COLLATERAL LLC
Reel/Frame 073521/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2021
From: HETHERINGTON, MARK ANDREW; SCHNARR, CHRIS
To: CANOPY HEALTH INNOVATIONS
Reel/Frame 057130/0652 →
CHANGE OF NAME Recorded Aug 10, 2021
From: CANOPY HEALTH INNOVATIONS
To: 10607410 CANADA INC.
Reel/Frame 057142/0471 →
MERGER Recorded Aug 10, 2021
From: 10607410 CANADA INC.
To: STARKCO HOLDINGS INC.
Reel/Frame 057142/0474 →
MERGER Recorded Aug 10, 2021
From: STARKCO HOLDINGS INC.
To: TWEED INC.
Reel/Frame 057142/0616 →
Continuity (3)
Continuation 16671469 · Nov 1, 2019
Provisional Application 62754984 · Nov 2, 2018
Related Publication 20210361592A1 · Nov 25, 2021
Cited By (1)
US 12,442,024